Halberd (Halberd) Accounts Receivable : $0.00 Mil (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Halberd's accounts receivables for the quarter that ended in Jul. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Halberd's Days Sales Outstanding for the quarter that ended in Jul. 2023 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Halberd's Net-Net Working Capital per share for the quarter that ended in Jul. 2023 was $-0.00.

Halberd Accounts Receivable Historical Data

The historical data trend for Halberd's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Accounts Receivable Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Accounts Receivable

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Accounts Receivable	-	-	-

Halberd Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Halberd Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Halberd's Days Sales Outstanding for the quarter that ended in Jul. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.003	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Halberd's accounts receivable are only considered to be worth 75% of book value:

Halberd's Net-Net Working Capital Per Share for the quarter that ended in Jul. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.007	+	0.75 * 0	+	0.5 * 0	-	0.939
-	0.001	-	0)	/	565.875
=	-0.00

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Halberd Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Halberd's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236